TIM-3 Does Not Act as a Receptor for Galectin-9

English version České info

T cell immunoglobulin and mucin protein 3 (TIM-3) is a type I cell surface protein that was originally identified as a marker for murine T helper type 1 cells. TIM-3 was found to negatively regulate murine T cell responses and galectin-9 was described as a binding partner that mediates T cell inhibitory effects of TIM-3. Moreover, it was reported that like PD-1 the classical exhaustion marker, TIM-3 is up-regulated in exhausted murine and human T cells and TIM-3 blockade was described to restore the function of these T cells. Here we show that the activation of human T cells is not affected by the presence of galectin-9 or antibodies to TIM-3. Furthermore, extensive studies on the interaction of galectin-9 with human and murine TIM-3 did not yield evidence for specific binding between these molecules. Moreover, profound differences were observed when analysing the expression of TIM-3 and PD-1 on T cells of HIV-1-infected individuals: TIM-3 was expressed on fewer cells and also at much lower levels. Furthermore, whereas PD-1 was preferentially expressed on CD45RA⁻CD8 T cells, the majority of TIM-3-expressing CD8 T cells were CD45RA⁺. Importantly, we found that TIM-3 antibodies were ineffective in increasing anti-HIV-1 T cell responses in vitro, whereas PD-L antibodies potently reverted the dysfunctional state of exhausted CD8 T cells. Taken together, our results are not in support of an interaction between TIM-3 and galectin-9 and yield no evidence for a functional role of TIM-3 in human T cell activation. Moreover, our data indicate that PD-1, but not TIM-3, is a promising target to ameliorate T cell exhaustion.

Vyšlo v časopise: TIM-3 Does Not Act as a Receptor for Galectin-9. PLoS Pathog 9(3): e32767. doi:10.1371/journal.ppat.1003253
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003253

Souhrn

Zdroje

1. HodiFS, O'DaySJ, McDermottDF, WeberRW, SosmanJA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.

2. BarberDL, WherryEJ, MasopustD, ZhuB, AllisonJP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682–687.

3. TrautmannL, JanbazianL, ChomontN, SaidEA, GimmigS, et al. (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12: 1198–1202.

4. DayCL, KaufmannDE, KiepielaP, BrownJA, MoodleyES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354.

5. PeretzY, HeZ, ShiY, Yassine-DiabB, GouletJP, et al. (2012) CD160 and PD-1 Co-Expression on HIV-Specific CD8 T Cells Defines a Subset with Advanced Dysfunction. PLoS Pathog 8: e1002840.

6. Grabmeier-PfistershammerK, SteinbergerP, RiegerA, LeitnerJ, KohrgruberN (2011) Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr 56: 118–124.

7. TopalianSL, HodiFS, BrahmerJR, GettingerSN, SmithDC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.

8. BrahmerJR, TykodiSS, ChowLQ, HwuWJ, TopalianSL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.

9. BlackburnSD, ShinH, HainingWN, ZouT, WorkmanCJ, et al. (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10: 29–37.

10. JonesRB, NdhlovuLC, BarbourJD, ShethPM, JhaAR, et al. (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205: 2763–2779.

11. ValiB, JonesRB, SakhdariA, ShethPM, ClaytonK, et al. (2010) HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 40: 2493–2505.

12. FourcadeJ, SunZ, BenallaouaM, GuillaumeP, LuescherIF, et al. (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207: 2175–2186.

13. McMahanRH, Golden-MasonL, NishimuraMI, McMahonBJ, KemperM, et al. (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 120: 4546–4557.

14. ZhuC, AndersonAC, SchubartA, XiongH, ImitolaJ, et al. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245–1252.

15. LeitnerJ, KuscheiW, Grabmeier-PfistershammerK, WoitekR, KriehuberE, et al. (2010) T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. J Immunol Methods 362: 131–141.

16. WangF, WanL, ZhangC, ZhengX, LiJ, et al. (2009) Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology 214: 342–349.

17. SehrawatS, SuryawanshiA, HirashimaM, RouseBT (2009) Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. J Immunol 182: 3191–3201.

18. SehrawatS, ReddyPB, RajasagiN, SuryawanshiA, HirashimaM, et al. (2010) Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog 6: e1000882.

19. ElahiS, NikiT, HirashimaM, HortonH (2012) Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood 119: 4192–4204.

20. HastingsWD, AndersonDE, KassamN, KoguchiK, GreenfieldEA, et al. (2009) TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 39: 2492–2501.

21. AndersonAC, AndersonDE, BregoliL, HastingsWD, KassamN, et al. (2007) Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318: 1141–1143.

22. SakhdariA, MujibS, ValiB, YueFY, MacparlandS, et al. (2012) Tim-3 Negatively Regulates Cytotoxicity in Exhausted CD8(+) T Cells in HIV Infection. PLoS One 7: e40146.

23. LiH, WuK, TaoK, ChenL, ZhengQ, et al. (2012) Tim-3/galectin-9 signaling pathway mediates T cell dysfunction and predicts poor prognosis in patients with HBV-associated hepatocellular carcinoma. Hepatology 56: 1342–51.

24. MonneyL, SabatosCA, GagliaJL, RyuA, WaldnerH, et al. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536–541.

25. SabatosCA, ChakravartiS, ChaE, SchubartA, Sanchez-FueyoA, et al. (2003) Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 4: 1102–1110.

26. Sanchez-FueyoA, TianJ, PicarellaD, DomenigC, ZhengXX, et al. (2003) Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 4: 1093–1101.

27. RabinovichGA, DalyG, DrejaH, TailorH, RieraCM, et al. (1999) Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 190: 385–398.

28. SuEW, BiS, KaneLP (2011) Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 21: 1258–1265.

29. ZhouQ, MungerME, VeenstraRG, WeigelBJ, HirashimaM, et al. (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117: 4501–4510.

30. KhaitanA, UnutmazD (2011) Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 8: 4–11.

31. SteinbergerP, MajdicO, DerdakSV, PfistershammerK, KirchbergerS, et al. (2004) Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172: 2352–2359.

32. LeitnerJ, Grabmeier-PfistershammerK, MajdicO, ZlabingerG, SteinbergerP (2011) Interaction of antithymocyte globulins with dendritic cell antigens. Am J Transplant 11: 138–145.

33. FreemanGJ, CasasnovasJM, UmetsuDT, DeKruyffRH (2010) TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 235: 172–189.

34. DeKruyffRH, BuX, BallesterosA, SantiagoC, ChimYL, et al. (2010) T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol 184: 1918–1930.

35. NakayamaM, AkibaH, TakedaK, KojimaY, HashiguchiM, et al. (2009) Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113: 3821–3830.

36. FadokVA, BrattonDL, KonowalA, FreedPW, WestcottJY, et al. (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101: 890–898.

37. HuynhML, FadokVA, HensonPM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109: 41–50.

38. RavichandranKS, LorenzU (2007) Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 7: 964–974.

39. LeitnerJ, KlauserC, PicklWF, StocklJ, MajdicO, et al. (2009) B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol 39: 1754–1764.

40. PfistershammerK, MajdicO, StocklJ, ZlabingerG, KirchbergerS, et al. (2004) CD63 as an activation-linked T cell costimulatory element. J Immunol 173: 6000–6008.

41. PfistershammerK, KlauserC, PicklWF, StocklJ, LeitnerJ, et al. (2006) No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 36: 1104–1113.

42. KoberJ, LeitnerJ, KlauserC, WoitekR, MajdicO, et al. (2008) The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 38: 2678–2688.